USA v. Gibson, No. 20-3049 (2d Cir. 2023)
Annotate this Case
The government petitions for a panel rehearing of so much of the Second Circuit’s decision in United States v. Gibson, 55 F.4th 153 (2d Cir. 2022), as ruled that the 2015 removal of naloxegol from the federal controlled substances schedules promulgated under the Controlled Substances Act ("CSA"), 21 U.S.C. Sections 801-971, rendered those schedules categorically narrower than the New York drug schedules applicable to Defendant’s 2002 state-law conviction. The government's petition suggests that that ruling in the court’s opinion ("Opinion") was dictum rather than a holding and asks that the court issue an amended opinion so stating.
The Second Circuit granted rehearing in order to note the government's various positions on the comparability of the state and federal drug schedules and to flag some defects in the petition's characterizations of the record. However, the court denied the request for an amended opinion. The court explained that the comparability of the New York's 2002 drug schedules and the current federal drug schedules was an issue that the district court was required to, and did, decide in order to make a determination as to what Defendant’s Guidelines sentence would be. This Court was required to and did, determine whether the district court's decision was correct.
This opinion or order relates to an opinion or order originally issued on December 6, 2022.
Some case metadata and case summaries were written with the help of AI, which can produce inaccuracies. You should read the full case before relying on it for legal research purposes.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.